ACT Genomics completed investment on route to become the leading DNA sequencing-based cancer solution provider in Asia
TAIPEI, Sept. 26, 2018 /PRNewswire/ -- ACT Genomics Holdings Company Limited ("ACTG" or "Company") is pleased to announce the completion of the latest round of equity financing from a group of international investors co-led by CLSA Capital Partners.
Founded in 2014, ACTG is the Asia leading DNA sequencing-based cancer solution providers and transforms science into actionable solutions empowering clinicians and patients with evidence-based information to fight cancer. Company's mission is to provide every cancer patient personalized genomic information-based treatment plans through the cutting-edge Next Generation Sequencing ("NGS") platform, Asian genome database, leading professional bioinformatics and biomedical team in Asia, medical report, and integrated services.
"New capital from this round of investment will support ACTG's strategic plan to strengthen our footprints and capabilities across the Pan-Asia region," said by Dr. Hua Chien Chen, Co-Founder and CEO of ACTG. "ACTG will continue its business expansion including the establishment of additional CAP-accredited NGS laboratories in Hong Kong, new products research and development, expansion of clinical services operations in Asia, and drug development collaboration with global and regional bio-pharmaceutical companies."
ACTG's flagship NGS panel, ACTOnco®+, investigates 440 cancer-related genes by incorporating a signaling pathway design. ACTOnco®+ provides optimal treatment suggestion to clinicians, including targeted therapies, hormonal therapies, chemotherapies, and immunotherapies, for all solid tumor types.
Currently, Company has operations in Taiwan, Hong Kong, Singapore and Japan. ACTG has also established a joint venture with Canon Medical System Corporation in Japan to operate cancer genomic profiling service and sequencing data analysis covering Japan.
Founded in 2014, ACTG provides optimal cancer treatment plan, cancer relapse and drug resistance monitoring as well as cancer risk assessment and immunotherapy evaluation through DNA sequencing-based technology. Company achieves precise cancer genetic variants detection with minimum tumor samples, and delivers to every cancer patient personalized genomic information-based treatment plans through cutting-edge NGS platform, medical report and integrated services. Company also provides comprehensive data analysis on cancer genomics applying Artificial Intelligence and integrates genomic databases information with Asia specific genome profiling.
ACTG's comprehensive portfolio received the 2017 Asia Pacific Molecular Diagnostics Product Line Strategy Leadership Award by Frost & Sullivan.
Victor Chan, Chief Finance Officer, Email: email@example.com;
Angus Wu, Sr. Associate Director, Business Development, Email: firstname.lastname@example.org